|
Retinal telangiectasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
RETINAL TELANGIECTASIA IN PATIENTS WITH PATHOLOGIC MYOPIA: A CASE SERIES.
|
29232337 |
2019 |
|
Severe myopia
|
0.100 |
Biomarker
|
disease |
BEFREE |
High myopia and pathologic myopia are common causes of visual morbidity.
|
30030628 |
2018 |
|
Myopia
|
0.090 |
Biomarker
|
disease |
BEFREE |
Myopia is a highly frequent ocular disorder worldwide and pathologic myopia is the 4th most common cause of irreversible blindness in developed countries.
|
30391362 |
2019 |
|
Staphyloma posticum
|
0.040 |
Biomarker
|
disease |
BEFREE |
Posterior staphyloma in pathologic myopia.
|
30537538 |
2019 |
|
Severe myopia
|
0.100 |
Biomarker
|
disease |
BEFREE |
High myopia may develop to pathologic myopia, which brings severe visual impairment; however, the etiology is not fully understood.
|
31547036 |
2019 |
|
Myopia
|
0.090 |
Biomarker
|
disease |
BEFREE |
Pathologic myopia described as myopia accompanied by severe deformation of the eye besides excessive elongation of eye, is usually a genetic heterogeneous disorder characterized by extreme, familial, early-onset vision loss.
|
28837730 |
2017 |
|
Low Vision
|
0.010 |
Biomarker
|
disease |
BEFREE |
Pathologic myopia is a leading cause of visual impairment in East Asia.
|
30747064 |
2018 |
|
Severe myopia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genomic interval of 2.2 centiMorgans (cM) was defined on chromosome band 18p11.31 using 7 families diagnosed with autosomal dominant high myopia and was designated the MYP2 locus.
|
15723005 |
2005 |
|
Severe myopia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A recent linkage analysis of seven families with autosomal dominant high myopia has identified one locus (MYP2) for high myopia on chromosome 18p11.31 (Young et al.: Am J Hum Genet 1998;63:109-119).
|
11449316 |
2001 |
|
X-linked retinitis pigmentosa
|
0.010 |
Biomarker
|
disease |
BEFREE |
All members of this RP-PM family underwent a complete ophthalmic examination.
|
27995965 |
2016 |
|
Severe myopia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the terms high myopia and pathologic myopia are often used interchangeably, they do not refer to the same eye disease.
|
30391362 |
2019 |
|
Disorder of eye
|
0.020 |
Biomarker
|
group |
BEFREE |
Although the terms high myopia and pathologic myopia are often used interchangeably, they do not refer to the same eye disease.
|
30391362 |
2019 |
|
Retinal Detachment
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Amniotic membrane for retinal detachment due to paravascular retinal breaks over patchy chorioretinal atrophy in pathologic myopia.
|
31766876 |
2020 |
|
Retinal Perforations
|
0.010 |
Biomarker
|
group |
BEFREE |
Amniotic membrane for retinal detachment due to paravascular retinal breaks over patchy chorioretinal atrophy in pathologic myopia.
|
31766876 |
2020 |
|
Chorioretinal atrophy
|
0.030 |
Biomarker
|
disease |
BEFREE |
Amniotic membrane for retinal detachment due to paravascular retinal breaks over patchy chorioretinal atrophy in pathologic myopia.
|
31766876 |
2020 |
|
Severe myopia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Among all the patients with different types of refractive errors, myopia was found in 47.4%, high myopia in 6.8% and pathologic myopia in 2.2%.
|
30209314 |
2018 |
|
Myopia
|
0.090 |
Biomarker
|
disease |
BEFREE |
Approaches to prevent myopia-related blindness should therefore attempt to prevent or delay the onset of myopia among children by increased outdoor time; retard progression from low/mild myopia to HM, through optical (e.g., defocus incorporated soft contact lens, orthokeratology, and progressive-additional lenses) and pharmacological (e.g., low dose of atropine) interventions; and/or retard progression from HM to PM through medical/surgical treatments (e.g., anti-VEGF therapies, macula buckling, and scleral crosslinking).
|
30707221 |
2019 |
|
Severe myopia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Approaches to prevent myopia-related blindness should therefore attempt to prevent or delay the onset of myopia among children by increased outdoor time; retard progression from low/mild myopia to HM, through optical (e.g., defocus incorporated soft contact lens, orthokeratology, and progressive-additional lenses) and pharmacological (e.g., low dose of atropine) interventions; and/or retard progression from HM to PM through medical/surgical treatments (e.g., anti-VEGF therapies, macula buckling, and scleral crosslinking).
|
30707221 |
2019 |
|
Central retinal vein occlusion
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy.
|
31531945 |
2019 |
|
Venous retinal branch occlusion
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy.
|
31531945 |
2019 |
|
Diabetic macular edema
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy.
|
31531945 |
2019 |
|
Exudative age-related macular degeneration
|
0.030 |
Biomarker
|
disease |
BEFREE |
Aqueous humour from eyes with central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), diabetic macular oedema (DME), neovascular age-related macular degeneration (nAMD) or pathologic myopia associated choroidal neovascularization (pmCNV) was sampled prior to 1st (n = 144) and 2nd (n = 48) intravitreal anti-VEGF therapy.
|
31531945 |
2019 |
|
Exudative age-related macular degeneration
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Choroidal neovascularization (CNV) in adults is most commonly associated with neovascular age-related macular degeneration (AMD) and pathologic myopia.
|
30727875 |
2018 |
|
Age related macular degeneration
|
0.040 |
Biomarker
|
disease |
BEFREE |
Choroidal neovascularization (CNV) in adults is most commonly associated with neovascular age-related macular degeneration (AMD) and pathologic myopia.
|
30727875 |
2018 |
|
Glycogen storage disease type II
|
0.010 |
Biomarker
|
disease |
BEFREE |
Choroidal neovascularization (CNV) in adults is most commonly associated with neovascular age-related macular degeneration (AMD) and pathologic myopia.
|
30727875 |
2018 |